Akero Therapeutics, Inc.
AKRO
$37.63
$0.190.51%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -252.06M | -237.22M | -204.18M | -179.27M | -151.76M |
| Total Depreciation and Amortization | 18.00K | 5.00K | 9.00K | 19.00K | 29.00K |
| Total Amortization of Deferred Charges | 607.00K | 553.00K | 505.00K | 797.00K | 785.00K |
| Total Other Non-Cash Items | 18.33M | 16.71M | 15.32M | 13.47M | 12.25M |
| Change in Net Operating Assets | 3.00M | 8.32M | -2.59M | 9.11M | -6.67M |
| Cash from Operations | -230.11M | -211.64M | -190.94M | -155.88M | -145.37M |
| Capital Expenditure | -999.00K | -999.00K | -999.00K | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -108.71M | -111.20M | -309.96M | -183.36M | -223.62M |
| Cash from Investing | -109.71M | -112.19M | -310.96M | -183.36M | -223.62M |
| Total Debt Issued | 10.00M | 10.00M | 10.00M | 10.00M | 15.00M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 436.69M | 361.20M | 358.88M | 695.85M | 339.09M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -844.00K | -846.00K | -782.00K | -747.00K | -776.00K |
| Cash from Financing | 445.85M | 370.36M | 368.10M | 705.10M | 353.32M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 106.03M | 46.52M | -133.80M | 365.86M | -15.67M |